Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program

Astellas

Status: Completed

Conditions: Plaque Psoriasis

Study type: Observational

Funder types: Industry

Identifiers

NCT00371774

CA-08

Details and patient eligibility

About

Purpose:

To develop a real time national clinical database to support and share best practices,

1. To generate hypotheses for future clinical research
2. To understand how AMEVIVE is used in routine clinical practice/real world setting.

Each patient visit will include the following observational endpoints:

1. AMEVIVE dosing
2. Number of courses
3. Concomitant treatment
4. Response to treatment (patient and physician global assessments)
5. Status of other psoriasis-related medical conditions
6. Time to re-treatment.

Enrollment: 426 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Amevive is clinically indicated for the patient

Exclusion criteria

• Amevive is contraindicated for the patient

Trial design

426 participants in 1 patient group

1

Description:

Dermatologic patients in Canada for which Amevive is clinically indicated